- Paolo Bruzzi, National Cancer Research Institute
- Carlos Caldas, Cambridge Research Institute
- Ian Cree, Warwick Medical School, Coventry
- Shoukat Dedhar, British Columbia Cancer Agency
- John A Hartley, University College London
- Manami Inoue, University of Tokyo
- Mark McKeage, University of Auckland
- Christophe Nicot, Kansas University Medical Center
- Stephen P Povoski, The Ohio State University
- Charles Rosser, University of Hawaii Cancer Center
- Dirk Vordermark, Martin Luther University Halle-Wittenberg
- Dafne Solera, BioMed Central
Silica microparticles loaded with doxorubicin (DOX) and modified with a mesothelin specific antibody demonstrate higher effectiveness and lower toxicity than DOX systemic treatment in a mouse xenograft model of human peritoneal mesothelioma.
Newly appointed Section Editor Stephen Povoski and Deputy Nathan Hall comment on plans to expand the scope of the BMC Cancer Clinical Oncology section, as surgical oncology and cancer imaging join forces with chemotherapy and radiation.
Ferdinando Mannello and Daniela Ligi review breast cancer biomarkers that mirror the tumor microenvironment and discuss the potential of the nipple aspirate fluid secretome as a source of novel markers for early detection.
BMC Cancer 2013, 13:563
News from the web
- 13 December 2013
- Cetuximab fails in second-line combination for recurrent NSCLC
- 10 December 2013
- Pemetrexed, paclitaxel regimens equally effective in NSCLC
- 09 December 2013
- Early tumor shrinkage predicts targeted therapy efficacy in RCC
BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.
It is journal policy to publish work deemed by peer reviewers to be a coherent and sound addition to scientific knowledge and to put less emphasis on interest levels, provided that the research constitutes a useful contribution to the field.
Join the Editorial Board!
Are you interested in becoming an Editorial Board member for BMC Cancer and helping to maintain the editorial standards and ethos of this growing journal? To volunteer as an Associate Editor, please simply contact us at email@example.com, enclosing a summary of your research interests and relevant expertise. We look forward to hearing from you.
Christudas Morais, David W Johnson, David A Vesey, and Glenda C Gobe1BMC Cancer 2013, 13:14 (10 January 2013)
Section Editor's profile
Mark McKeage is a medical oncologist and associate professor in the department of pharmacology and clinical pharmacology and co-director of the Auckland Cancer Society Research Centre at the university of Auckland, New Zealand. His current research focuses on how membrane transporters determine response and handling of platinum-based anticancer drugs. In addition, he leads a programme of phase I oncology trials at his centre.
"BMC Cancer is the leading Open Access international journal in the field of oncology. By publishing over 500 articles per year, BMC Cancer offers rapid dissemination of the most recent information of interest to the broad oncology science community."
Prof McKeage is the Section Editor of the Clinical oncology- medical oncology and pharmacology section of BMC Cancer.
BMC series blog
- 03 December 2013
- Highlights of the BMC-series: November 2013
- 20 November 2013
- APHA: For science. For action. For health.
- 18 November 2013
- BMC Geriatrics at the 2013 BGS Autumn Scientific Meeting